ReviewMedicine2025
Placental mesenchymal dysplasia: A rare case report and literature review.
Review in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Placental mesenchymal dysplasia: diagnostic and management insights from a case report and literature review.Archives of gynecology and obstetrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
rationalePlacental mesenchymal dysplasia (PMD) is a rare placental disorder that poses diagnostic challenges and is often misdiagnosed as a trophoblastic tumor. While PMD is associated with fetal growth restriction, intrauterine fetal death, and pregnancy-induced hypertension, it does not involve malignant trophoblastic disease. Accurate diagnosis is crucial for optimizing maternal and fetal outcomes. PATIENT CONCERNS: A 30-year-old female, gravida 3, para 1, with an uncomplicated medical history, presented with early pregnancy bleeding, which was managed with oral progesterone. Ultrasound at 13 weeks showed normal fetal morphology but a honeycomb-like placental appearance. At 23 weeks, ultrasound revealed fetal growth restriction, thickening of the placenta, and abnormal umbilical artery flow. Magnetic resonance imaging at 32 weeks confirmed abnormal placental masses. DIAGNOSES: Ultrasound, magnetic resonance imaging, and genetic testing (noninvasive prenatal testing, amniocentesis, and chromosomal microarray analysis) confirmed normal karyotype and identified distinctive placental abnormalities. Histopathological examination revealed edematous villi, fibromuscular hyperplasia, and amyloid-like protein deposits, consistent with PMD.
interventionsPrenatal care included enoxaparin sodium and management of fetal distress at 32 weeks with a cesarean section. Magnesium sulfate and dexamethasone were administered for fetal protection. OUTCOMES: Both mother and infant were healthy postpartum. The infant had favorable Apgar scores, and the patient's blood pressure was managed with antihypertensive therapy. Maternal β-human chorionic gonadotropin levels remained normal throughout the pregnancy and postpartum. LESSONS: PMD is an exceptionally rare placental disorder with a low incidence. It often presents with atypical ultrasound findings and can easily be misdiagnosed as a trophoblastic tumor, leading to unnecessary interventions. Diagnosing PMD is challenging, particularly in the absence of specific clinical symptoms. Clinicians must enhance awareness of this rare condition, prioritize early and accurate diagnosis through advanced imaging and histopathology, and differentiate PMD from other placental pathologies to ensure appropriate management and improve maternal-fetal outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.